The growing number of approved cell and gene therapies — CAR-T treatments, gene replacement therapies, and other advanced biologics — has introduced cold chain and handling requirements considerably more demanding than the standard refrigerated or frozen storage most hospital pharmacies were already equipped to manage. Some products require storage at cryogenic temperatures well below what a standard pharmacy freezer can maintain.
What Makes This Category Different
- Ultra-low and cryogenic temperature requirements for some products, requiring specialized freezer infrastructure and liquid nitrogen or vapor-phase storage capability many pharmacies didn't previously need
- Patient-specific manufacturing for autologous cell therapies means there is no substitute product if a specific patient's therapy is compromised in transit or storage — a single-point-of-failure risk unlike almost any other pharmacy product
- Extremely narrow handling windows for some products between thaw and administration, requiring precise scheduling coordination between pharmacy, nursing, and the treating physician
Building Adequate Infrastructure
Hospitals establishing cell and gene therapy programs need to invest in appropriate storage equipment well before their first patient treatment, along with staff training specific to each product's unique handling protocol, since generic biologic handling training doesn't adequately prepare staff for the precision this category demands.
The Stakes of Getting This Wrong
Given the patient-specific manufacturing model for many cell therapies and the very high cost of each dose, a handling or storage failure isn't simply a financial loss — it can mean a patient loses access to their only manufactured dose of a potentially curative therapy, with a lengthy and clinically risky re-manufacturing process required to get a replacement.
Facilities building specialty pharmacy infrastructure can review Healix Medical Supply's pharmacy supply catalog.
